Does psoriasis happen in skin folds and the genital area?
Yes, and it has a name of its own. I read NIAMS, which records inverse psoriasis as a subtype and places it in skin folds. It names the armpits, the groin and under the breasts. The AAD names the same fold sites, and names the genitals among the delicate areas it describes treating. Evidence Evidence
Why this matters
- Sources cited, not yet graded
That makes this a named pattern rather than an odd version of your psoriasis. The sites are the ones that rub and stay damp. NIAMS records that rubbing and sweating can make inverse psoriasis worse. Nothing about the place makes it a smaller problem than a patch on an elbow.
Considerations
- Depends on you
Neither page counts how many people it reaches. Neither says who gets it, or when in the course of the condition. Neither can tell you that what you can see is psoriasis. Looking at skin is work for a clinician, and it is not something I can do from here.
Questions for your dermatologist
Does what I have in this fold look like inverse psoriasis to you?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Will you look at this area, or send me to someone who will?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Why is it smooth instead of scaly?
Because of where it sits. NIAMS describes inverse psoriasis as smooth patches of inflamed skin in a fold. It describes psoriasis elsewhere as thick, scaly skin that itches or burns. The thick scale in the pictures may simply not be there. Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
So a shiny, sore, well-edged patch in the groin or under a breast can still be psoriasis. NIAMS records that rubbing and sweating make it worse, which is the daily reality of a fold. The AAD pages I read treat the genitals and the fold sites as delicate skin, handled apart from thicker sites.
Considerations
- Depends on you
Sore, smooth skin in a warm fold is also how several other things look, including infections. That is why a patch there is often treated as one first. None of these sources separates them from a description or a photograph. That separation is a clinical judgement, and it is worth asking for by name.
Questions for your dermatologist
This does not look like the psoriasis pictures. Could it still be psoriasis?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What else could this be, and how would you tell the difference?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Is there a daily habit that helps, like what I wear?
The AAD lists loose-fitting underwear and clothing among its self-care steps for genital psoriasis, because tight-fitting clothing can cause friction. Evidence
Why this matters
- Sources cited, not yet graded
The same list covers the rest of the day. Use the treatment your dermatologist prescribed for the area, and tell them if it irritates the skin. Use a mild fragrance-free cleanser, and moisturize gently with a fragrance-free product after bathing. Use quality toilet paper, and avoid getting urine or feces on the psoriasis. Get plenty of fiber in the diet.
Considerations
- Depends on you
The page names no fabric, so it does not say cotton over synthetic or any other material. It does not cover clothing for psoriasis outside the genital area. It does not say how much friction from a garment is enough to matter for one person.
Questions for your dermatologist
I already wear ___ most days - does that count as loose-fitting enough?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Which of these self-care steps matters most for what you see on me?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Does a patch there change how severe my psoriasis counts as?
It can, and that is a reason to have it written down. The International Psoriasis Council names the genitalia as a high-impact site. On its scale, psoriasis on a high-impact site makes a person a candidate for systemic therapy. That holds whatever share of the body is covered. Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
I compared the two statements, and the National Psoriasis Foundation says the same in its own words. It states that moderate-to-severe psoriasis is not determined solely by body surface area of 10 per cent. It lists the genitals among high-impact sites. NICE assesses psoriasis across the skin, the nails, high-impact sites, daily life and any joint concerns.
Considerations
- Depends on you
Neither body sets a health plan rule. IPC is a professional consensus and NPF is an advocacy organization. NICE is UK guidance and sets no US sequence or coverage. None of them decides what your plan does with your case.
Questions for your dermatologist
Does the site of this change what counts as moderate-to-severe for me?
Saving keeps this on your device and needs JavaScript, which is off in this browser.If we ask for a stronger treatment, will the site be recorded in my notes?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
How do I raise it, and what about sex and relationships?
One sentence does the whole job. Say that you also have psoriasis in a skin fold and in the genital area, and that you want it looked at. No explanation is owed for why it took until now. Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
Having it in the groin or the folds is one thing. Finding a way to raise it with a doctor is another, and readers ask about that with real shame attached. The National Psoriasis Foundation page I read says to bring a symptom record to the appointment and share it, and to note which areas are affected. A record that names the site raises the subject for you. NIAMS records that psoriasis carries risk for low self-esteem, anxiety and depression, so the weight of this is not only skin.
Considerations
- Depends on you
The 2021 case-control study I read compared 100 people who had moderate-to-severe plaque psoriasis with 101 people who did not. Significantly more of the psoriasis group was divorced, and that group scored lower on a marriage-quality index. It is one study of 201 people in Italy. It compares groups on average and predicts nothing about one relationship.
Questions for your dermatologist
Can the fold and genital sites go in my notes, in writing?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Who here can help with the part of this that is reaching my relationship?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What gets considered for skin that thin?
Different things from an elbow, and the reason is the skin itself. I read the AAD on this. It says strong corticosteroid products on thin skin, such as the face, carry a risk of skin thinning, spider veins and stretch marks. The National Psoriasis Foundation lists skin thinning, pigment change, easy bruising and stretch marks among topical steroid side effects. Evidence Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
That is why the AAD describes Protopic (tacrolimus) ointment and Elidel (pimecrolimus) cream for delicate areas, including the genitals, and for inverse psoriasis. Both are approved for eczema rather than psoriasis, so use here is off-label. NICE maps topical, phototherapy and systemic options against the whole assessment, high-impact sites included.
Considerations
- Depends on you
I print no strength, no amount, no frequency and no course length. The AAD records an FDA warning of a possible increased risk of lymphoma or skin cancer with those two medicines. The National Psoriasis Foundation notes that covered or prolonged steroid use raises absorption. What fits you is for the person prescribing.
Questions for your dermatologist
What would you use on skin this thin, and what are its limits?
Saving keeps this on your device and needs JavaScript, which is off in this browser.When should we look at this area again to see whether it worked?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence and update context
This optional layer shows the evidence boundary I reviewed as of 2026-09-19.
- What this evidence supports
- That makes this a named pattern rather than an odd version of your psoriasis. The sites are the ones that rub and stay damp. NIAMS records that rubbing and sweating can make inverse psoriasis worse. Nothing about the place makes it a smaller problem than a patch on an elbow.
- What it does not establish
- Neither page counts how many people it reaches. Neither says who gets it, or when in the course of the condition. Neither can tell you that what you can see is psoriasis. Looking at skin is work for a clinician, and it is not something I can do from here.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that poor sleep quality is a listed symptom of psoriasis. Also lists patches of thick, red, scaly skin that itch or burn, and dry, cracked skin that itches or bleeds. Supports that psoriasis carries risk for mental-health concerns including low self-esteem, anxiety, and depression. Supports that managing common triggers, such as stress and skin injuries, can help keep symptoms under control. Supports, by subtype, that guttate psoriasis outbreaks are often triggered by an upper respiratory infection such as strep throat. Also supports that pustular psoriasis symptoms can be triggered by medications, infections, stress, or certain chemicals. Also supports that erythrodermic psoriasis can be triggered by a bad sunburn or certain medications including corticosteroids. Also supports, by subtype, that inverse psoriasis appears as smooth patches of inflamed skin in skin folds. It names the armpits, the groin, and under the breasts as those folds. It records that rubbing and sweating can make inverse psoriasis worse.
What it does not support
Does not give a percentage of patients affected. Does not measure how much sleep is lost. Does not establish that treating the skin fixes the sleep problem for any one person. Its trigger information is organized by psoriasis subtype, not as one general list for plaque psoriasis specifically. It counts nothing for inverse psoriasis either. It gives no share of people affected in a fold or genital site, and it names no treatment for one.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Italian Journal of Dermatology and Venereology (Di Altobrando A, Vara G, Filippi F, Sacchelli L, Patrizi A, Bardazzi F)Observational study · Clinical research, tier 2Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The full text, including any funding or competing-interest disclosure, is not open access; only the indexed PubMed abstract could be verified.
What this source supports
Supports that a case-control study followed 201 married or divorced people: 100 with moderate-to-severe plaque psoriasis, 101 without. A significantly higher number of the psoriasis group was divorced. Supports that people with psoriasis scored lower than the comparison group on every question of the Quality Marriage Index, and on its total score. Supports that the survey question about how happy the marriage was weighed more heavily for people without psoriasis. Supports that the question about how strong the marriage was weighed more heavily for people with psoriasis.
What it does not support
Does not give a divorce rate or percentage for either group - only that the psoriasis group's number was significantly higher. One case-control study of 201 people, all from Italy. Studied moderate-to-severe plaque psoriasis only. Compares two groups on average; it does not predict any one relationship.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- International Psoriasis CouncilGuideline · Clinical research, tier 2Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The International Psoriasis Council names its corporate members on its own site (psoriasiscouncil.org/about/corporate-members/, checked 2026-09-11). The top tier names AbbVie, Johnson & Johnson, Eli Lilly, Novartis and Takeda. LEO Pharma, UCB, Almirall, Sun Pharma, Amgen, Alumis, Arcutis and Oruka sit below them. Those firms make the drugs this severity rule opens the door to. A wider rule on who qualifies is a wider market for them. The page says nothing about how that money relates to IPC independence.
What this source supports
Supports that IPC dropped the mild, moderate and severe scale. In its place a person is a candidate for topical therapy, or a candidate for systemic therapy. Supports that any one of three criteria is enough to be a candidate for systemic therapy. The first is psoriasis on 10% or more of the body surface. The second is psoriasis on a high-impact site. IPC names those sites as the face, palms, soles, genitalia, scalp and nails. The third is failure of topical therapy. Supports that IPC defines that failure in writing. It is not reaching clear or almost-clear skin after two four-week courses in a row. IPC gives clear or almost-clear as 1% or less body surface, with a physician global assessment of 0 or 1. Supports the source paper. It is Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol 2020 Jan;82(1):117-122. Supports that IPC's own June 2025 teaching deck lists payers among the groups it set out to move. That deck also names refusal to pay as a result of the older scale.
What it does not support
Does not set any health plan's coverage rule. This is a professional-society consensus. It is not a regulation and not a plan document. Does not say which systemic treatment follows once a person meets a criterion. It sets no dose, no frequency and no schedule. Does not give the number of experts who voted, the response rate, or their conflict-of-interest disclosures. IPC's own June 2025 deck states the body-surface threshold two ways. Its criteria summary says 10% or more. The slide expanding that criterion says above 10%. Does not establish that a given reader meets a criterion. It predicts nothing about what a plan will decide.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The National Psoriasis Foundation names its corporate members on its own site (psoriasis.org/corporate-members/, checked 2026-09-09). They include AbbVie, Johnson & Johnson, Leo Pharma, Lilly, Novartis, UCB, Amgen, Sun Pharma, Arcutis, Bristol Myers Squibb, Takeda, and Alumis. Several of those firms make the drugs step therapy and copay-card rules affect. NPF also lobbies against both practices. This number and its framing come from a group with a stake in the fight, even though NPF says it does not back one drug over another.
What this source supports
Supports that NPF adopted a two-class definition. Mild psoriasis can be managed with topical therapies. Moderate-to-severe psoriasis makes a person a candidate for advanced therapies. Supports its statement that "Moderate-to-severe psoriasis is not determined solely by body surface area (BSA) involvement of 10%." Supports that psoriasis on a high-impact site counts too. NPF gives those sites as the face, scalp, hands, feet, nails or genitals. It says such patients "should also be considered as having 'moderate-to-severe' disease". Supports that the same holds for people who cannot get adequate control from topical therapies. Supports its statement that "People with psoriasis should never be denied advanced care because of outdated measures."
What it does not support
Does not set any health plan's coverage rule and does not bind a payer. Does not name prior authorization, appeals or denial steps. Gives no appeal deadline and no appeal process. Does not say how much topical treatment counts as inadequate control, or over what period. Does not establish that a given reader is a candidate for a named therapy. It predicts nothing about what a plan will decide.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports bringing a symptom tracker, kept on paper or on a phone, to share with a doctor at an appointment. Supports clearly describing symptoms and noting changes in severity and affected areas as part of preparing for a visit.
What it does not support
Does not mention photographing skin changes specifically. The page shows no visible byline or update date. The site copyright year, 2026, is used here.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute for Health and Care ExcellenceGuideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports psoriasis assessment across skin, nails, high-impact sites, life impact and joint concerns; same-day specialist assessment for generalised pustular psoriasis or erythroderma; and a treatment map that includes topical, phototherapy and systemic options.
What it does not support
It is UK guidance and does not diagnose a reader, create a US treatment sequence, determine personal urgency from a description, or establish current US labeling or coverage.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that topical corticosteroids reduce redness, swelling, scaling and itch, and slow skin-cell growth. They come in strengths from very mild to extremely strong and are typically applied twice daily. Strong products on thin skin such as the face carry skin-thinning, spider-vein and stretch-mark risk. Most people see results with short twice-daily use, and no improvement after four to six weeks is a signal to return to the prescriber.
What it does not support
The page does not display its own separate revision date; the date recorded here matches the same AAD psoriasis treatment section’s dated overview page checked the same day. It does not name potency classes by number, give a percentage of people who improve, or set a maximum course length.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The organization provides patient education, but its editorial and funding independence for this page was not independently reviewed.
What this source supports
Supports that topical steroids range from super-potent to least potent, and that guidance advises not using one for longer than three weeks without checking with a clinician. Side effects include skin thinning, pigment change, easy bruising, stretch marks, redness and dilated blood vessels. Systemic absorption is a risk with widespread, prolonged or occluded use, and abruptly stopping a topical steroid can cause a psoriasis flare.
What it does not support
It does not name which specific product falls in which potency class, quantify how often a side effect occurs, or set a course length for any specific product or body site.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that tacrolimus ointment and pimecrolimus cream are FDA approved to treat atopic dermatitis (eczema), not psoriasis, so dermatologists prescribe either for psoriasis off-label. Supports use on plaque psoriasis on the face and other delicate areas including the genitals, and on inverse psoriasis (armpits, under the breasts, groin, or face). Supports that most people apply either medicine twice a day, and that no improvement after six weeks is a signal to check back with a dermatologist. Supports that the FDA warns of a possible increased risk of lymphoma or skin cancer, while noting dermatologists have not observed this increased risk in day-to-day practice.
What it does not support
The page does not display its own separate revision date; the date recorded here matches the same AAD psoriasis treatment section’s dated overview page checked the same day. It does not explain the calcineurin mechanism of action, name a percentage of people who improve, or state a retail price.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports eight self-care steps for genital psoriasis. Use the treatment a dermatologist prescribed for the area. Tell the dermatologist if a treatment irritates the skin. Use a mild, fragrance-free cleanser. Moisturize gently with a fragrance-free moisturizer after bathing. Use quality toilet paper. Avoid getting urine or feces on the psoriasis. Wear loose-fitting underwear and clothing, since tight-fitting clothing can cause friction. Get plenty of fiber in the diet.
What it does not support
The page displays no separate revision date or byline; the date recorded here matches the same AAD psoriasis treatment section's dated overview page, checked the same day. It does not name a fabric type, does not cover clothing choices for psoriasis outside the genital area, and does not quantify how much friction a garment must cause before it worsens psoriasis. It does not replace a dermatologist-prescribed treatment.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.